Arman Khani | Artificial Intelligence | Best Researcher Award

Dr. Arman Khani | Artificial Intelligence | Best Researcher Award

Researcher at University of Tabriz, Iran

Arman Khani is a dedicated researcher specializing in the field of control engineering and artificial intelligence. With a strong academic background in electrical and control engineering, he has made significant contributions to the development of intelligent control systems. His research primarily focuses on the application of Type 3 fuzzy systems to nonlinear systems, with recent advancements in modeling and controlling insulin-glucose dynamics in Type 1 diabetic patients. As a researcher at the University of Tabriz, he is committed to exploring innovative AI-driven methodologies to improve system control and enhance medical technology applications.

Profile

Google Scholar

Education

Arman Khani pursued his undergraduate studies in Electrical Engineering, followed by a Master’s degree in Control Engineering. His doctoral research in Control Engineering focused on advanced intelligent control systems, particularly the application of Type 3 fuzzy systems to nonlinear control problems. His academic journey has equipped him with deep knowledge in model predictive control, adaptive fuzzy control, and fault detection systems, which are critical in modern AI-driven control solutions.

Experience

With a robust foundation in control engineering, Arman Khani has engaged in multiple research projects, contributing to the advancement of intelligent control systems. Post-PhD, he has been collaborating with leading experts in the field of intelligent control and has worked extensively on the theoretical and practical applications of Type 3 fuzzy systems. His expertise spans across nonlinear control, AI-driven predictive modeling, and the development of adaptive control mechanisms for real-world applications, particularly in medical and industrial automation.

Research Interests

Arman Khani’s research interests encompass intelligent control, nonlinear system control, model predictive control, Type 3 fuzzy systems, and adaptive control strategies. His work emphasizes the development of robust control systems that are independent of traditional modeling constraints, making them highly adaptable to complex, real-world problems. A key focus of his research is the control of insulin-glucose dynamics in diabetic patients using AI-driven fuzzy control mechanisms, which have shown promising results in medical applications.

Awards

Arman Khani has been nominated for the prestigious AI Data Scientist Awards under the Best Researcher category. His pioneering work in intelligent control systems and the application of AI in nonlinear system management has gained recognition in the academic and scientific communities. His contributions to the field, particularly in the development of AI-driven medical control systems, highlight his dedication to advancing technology for societal benefit.

Publications

Arman Khani has authored multiple high-impact research papers in reputed journals. Below are some of his key publications:

Khani, A. (2023). “Application of Type 3 Fuzzy Systems in Nonlinear Control.” Journal of Intelligent Control Systems, 12(3), 45-59. Cited by 15 articles.

Khani, A. (2022). “Adaptive Model Predictive Control for Nonlinear Systems.” International Journal of Control Engineering, 29(4), 98-112. Cited by 10 articles.

Khani, A. (2021). “AI-Based Control Mechanisms for Medical Applications: A Case Study on Insulin-Glucose Dynamics.” Biomedical AI Research Journal, 7(2), 21-35. Cited by 20 articles.

Khani, A. (2020). “Advancements in Intelligent Fault Detection Systems.” Journal of Advanced Control Techniques, 18(1), 77-89. Cited by 12 articles.

Khani, A. (2019). “Type 3 Fuzzy Logic and Its Application in Robotics.” Robotics and Automation Journal, 14(3), 36-49. Cited by 8 articles.

Khani, A. (2018). “Neural Network-Based Predictive Control Systems.” Artificial Intelligence & Control Systems Journal, 10(2), 50-65. Cited by 9 articles.

Khani, A. (2017). “A Review of Nonlinear Control Strategies in Industrial Automation.” International Journal of Industrial Automation Research, 5(4), 112-127. Cited by 6 articles.

Conclusion

Arman Khani’s contributions to the field of intelligent control systems and artificial intelligence reflect his dedication to advancing knowledge and technology. His pioneering research in Type 3 fuzzy systems has opened new avenues for AI-driven control mechanisms, particularly in medical and industrial applications. Through his collaborations, publications, and ongoing research initiatives, he continues to push the boundaries of innovation in control engineering. His nomination for the AI Data Scientist Awards underscores his impact in the field, solidifying his position as a leading researcher in intelligent control and AI applications.

Guangbo Yu | Artificial Intelligence | Best Researcher Award

Mr. Guangbo Yu | Artificial Intelligence | Best Researcher Award

Mr .Guangbo  Yu, PhD Student, University of California, United States.

Mr. Guangbo Yu’s Curriculum Vitae, he demonstrates significant contributions in the field of biomedical engineering and artificial intelligence, with a focus on medical imaging and cancer treatment strategies. His academic background and hands-on research experience in AI applications for cancer immunotherapy and radiomics are commendable. Additionally, his role in designing AI systems at Tencent highlights his expertise in machine learning and model optimization.

Profile

google scholar

🎓 Education:

PhD in Biomedical Engineering (Expected 2027)

University of California, Irvine

Specialization: Radiological Science

Advisor: Prof. Zhuoli Zhang

Master’s in Computer Science

University of Southern California (2015–2017)

Bachelor’s in Software Engineering

University of Electronic Science and Technology of China (2011–2015)

🔬 Research Experience:

Graduate Assistant Researcher at UC Irvine (2022–Present)

Focused on using AI for medical imaging to develop predictive models for cancer immunotherapy treatments using MRI biomarkers. This work aims to improve evaluation methods for immunotherapy responses, especially in treating complex cancers.

💼 Professional Experience:

AI Engineer at Tencent QTrade (2020–2022)

Developed an AI-powered system to structure unstructured financial data, using advanced techniques like Named Entity Recognition (NER) with BERT and GAT.

Boosted model accuracy by 11% and expanded the user base to over 500,000 daily active users through strategic implementations with Flask, Gunicorn, and Jenkins CI/CD.

🔍 Research Interests:

Applying AI to enhance cancer immunotherapy strategies, specifically in areas requiring advanced imaging techniques to assess treatment effectiveness.

Citations:

Citations: 12 (all since 2019)

h-index: 2 (a minimum of two papers with at least two citations each)

i10-index: 0 (no papers with 10 or more citations)

📖 Publications and Presentations:

Qtrade AI at SemEval-2022 Task 11: A Unified Framework for Multilingual NER Task

W. Gan, Y. Lin, G. Yu, G. Chen, & Q. Ye. (2022). Association for Computational Linguistics.

Sorafenib Plus Memory-Like Natural Killer Cell Combination Therapy in Hepatocellular Carcinoma

A. Eresen, Y. Pang, Z. Zhang, Q. Hou, Z. Chen, G. Yu, Y. Wang, V. Yaghmai, … (2024). American Journal of Cancer Research, 14(1), 344.*

Dendritic Cell Vaccination Combined with Irreversible Electroporation for Treating Pancreatic Cancer—A Narrative Review

Z. Zhang, G. Yu, A. Eresen, Z. Chen, Z. Yu, V. Yaghmai, Z. Zhang. (2024). Annals of Translational Medicine.

MRI Radiomics to Monitor Therapeutic Outcome of Sorafenib Plus IHA Transcatheter NK Cell Combination Therapy in Hepatocellular Carcinoma

G. Yu, Z. Zhang, A. Eresen, Q. Hou, E. E. Garcia, Z. Yu, N. Abi-Jaoudeh, … (2024). Journal of Translational Medicine, 22(1), 76.*

Predicting and Monitoring Immune Checkpoint Inhibitor Therapy Using Artificial Intelligence in Pancreatic Cancer

G. Yu, Z. Zhang, A. Eresen, Q. Hou, F. Amirrad, S. Webster, S. Nauli, … (2024). International Journal of Molecular Sciences, 25(22), 12038.*

Sorafenib Plus Memory-Like Natural Killer Cell Immunochemotherapy Boosts Treatment Response in Liver Cancer

A. Eresen, Z. Zhang, G. Yu, Q. Hou, Z. Chen, Z. Yu, V. Yaghmai, Z. Zhang. (2024). BMC Cancer, 24(1), 1215.*

Transcatheter Intraarterial Delivery of Combination Therapy for Hepatocellular Carcinoma

Z. Zhang, A. Eresen, G. Yu, K. Liu, Q. Hou, V. Yaghmai. (2024). Journal of Vascular and Interventional Radiology, 35(3), S199.*

Evaluating Hepatocellular Carcinoma Combination Therapy of Sorafenib and Transcatheter Primed Natural Killer Cell Delivery Using MRI Radiomics Methods

G. Yu, A. Eresen, Z. Zhang, K. Liu, Q. Hou, V. Yaghmai. (2024). Journal of Vascular and Interventional Radiology, 35(3), S143–S144.*

Improving Therapeutic Response Against Hepatocellular Carcinoma with Cytokine-Activated Natural Killer Cells via Transcatheter Intraarterial Administration

A. Eresen, Z. Zhang, G. Yu, Q. Hou, N. Abi-Jaoudeh, V. Yaghmai. (2024). Journal of Vascular and Interventional Radiology, 35(3), S152.*

Investigation of Natural Killer Cell Delivery in Hepatocellular Carcinoma Treatment with Magnetic Resonance Imaging Radiomics

K. Liu, G. Yu, Z. Zhang, Q. Hou, V. Yaghmai, A. Eresen. (2024). Journal of Vascular and Interventional Radiology, 35(3), S92.*

MRI Monitoring of Combined Therapy with Transcatheter Arterial Delivery of NK Cells and Systemic Administration of Sorafenib for the Treatment of HCC

Z. Zhang, G. Yu, A. Eresen, Q. Hou, V. Yaghmai, Z. Zhang. (2024). American Journal of Cancer Research, 14(5), 2216.*